Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
MDJM LTD Announces Pricing of Upsized $6.0 Million Public Offering
-
Maxim Group Upgrades INVO Fertility (IVF) to Buy
-
Bond Debuts on NASDAQ: Ushering in a New Era of AI-Powered Preventative Personal Security
-
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
-
Maxim Group Downgrades Allbirds Inc (BIRD) to Hold
-
Elong Power closes $7.6 million public offering
-
Elong Power Holding Limited Announces Closing of US$7.6 Million Public Offering
-
Bond to Go Public on Nasdaq as Catalyst for Global Scale
-
Elong Power prices $7.6 million public offering at $3.16 per unit
-
Elong Power Holding Limited Announces Pricing of US$7.6 Million Public Offering
-
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
-
Maxim Group Starts Cadiz Inc (CDZI) at Buy
-
Maxim Group Starts InspireMD (NSPR) at Buy
-
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
-
Maxim Group Downgrades Quince Therapeutics Inc. (QNCX) to Hold
-
Saratoga Investment prices $100 million bond offering at 7.50%
-
Saratoga Investment Corp. Prices Public Offering of $100 Million 7.50% Notes Due 2031
-
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
-
Maxim Group Upgrades Apple (AAPL) to Buy
-
Saratoga Investment launches notes offering, receives BBB+ rating
-
Saratoga Investment Corp. Announces Offering of Notes and BBB+ Investment Grade Rating from Egan-Jones Ratings Company
-
INVO Fertility raises $7.5 million through warrant exercise agreement
-
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
-
Aprea Therapeutics raises $5.6 million in private placement
-
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Titan Mining Files Base Shelf Prospectus and Establishes ATM Program
-
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
-
EVA Live, Inc. Announces Uplisting to Nasdaq Stock Market LLC.
-
TRNR provides 2026 revenue guidance of more than $20 million
-
TRNR Publishes Shareholder Letter and Investor Presentation with 2026 Revenue Guidance of More Than $20M
-
Virtuix begins trading on NASDAQ under ticker VTIX
-
Virtuix Debuts Trading on Nasdaq Under Ticker Symbol “VTIX” Following 138% Year-over-Year Revenue Growth
-
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
-
Maxim Group Downgrades Co-Diagnostics (CODX) to Hold
-
Rezolve Ai completes $250 million financing round
-
Rezolve Ai Closes $250 Million Oversubscribed Financing, Enters 2026 With One of the Strongest Balance Sheets in AI Commerce
-
Rezolve AI raises $250 million in registered direct offering
-
Rezolve Ai Announces $250 Million Registered Direct Offering led by Existing and New Fundamental Institutional Investors
-
Maxim Group Starts Nouveau Monde Graphite Inc. (NMG) at Buy
-
Signing Day Sports closes $5.6 million public offering
-
Signing Day Sports Announces Closing of $5.6 Million Public Offering
-
Signing Day Sports prices $5.6 million public offering at $0.59 per share
-
Signing Day Sports Announces Pricing of $5.6 Million Public Offering
-
Ondas Holdings completes $1 billion stock offering with institutional investor
-
Ondas Holdings Inc. Announces Closing of $1 Billion Offering
-
Dogwood Therapeutics raises $12.5 million in registered direct offering
-
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
-
Rubico prices $4 million public offering at $0.60 per unit
-
Rubico Announces Pricing of $4.0 Million Public Offering
-
Ondas Holdings prices $1 billion stock and warrant offering at premium

